SPOTLIGHT: Adherex inks deal with GSK

Adherex Technologies of Research Triangle Park, North Carolina, has inked a deal in-licensing GSK's oncology product eniluracil -- with GSK retaining an option to buy it back -- and giving GSK an option to license Adherex's lead biotechnology compound, ADH-1. GSK also made a $3 million equity investment in Adherex. GSK's options in the deal could be collectively worth up to $220 million in milestones plus royalties. Release

Suggested Articles

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial. 

The purchase comes as AstraZeneca enters a 12-month period in which it plans to file for approval of about 10 assets.